SAP: How the Software Giant Defends Its Market Power
The Walldorf-based company has massively expanded its patent portfolio in recent years—and has long since stopped using it solely for defensive purposes. With over a thousand active intellectual property rights in the US and Europe, SAP has built a technological fortress that makes life difficult for competitors. In particular, the areas of process mining, cloud data access, and AI-powered decision-making are strategically protected. The bitter legal battle with Celonis shows just how seriously the Walldorf-based company is playing the game. Patents are becoming a tool for regulating the market. It sounds aggressive, but that is exactly the point.
At the same time, SAP is focusing on smart deals. The cross-licensing agreement with Google avoids costly legal battles, and joining the LOT Network is a similar step. Important for investors is the new Defence Innovation Hub, which could create greater digital readiness and resilience in security-critical IT areas. Here, specialized architectures are being developed that go far beyond standard ERP functions and are protected by SAP’s own patents. Although the European Commission recently reached an agreement on competition issues, SAP had to make concessions regarding customers’ ability to switch providers, the foundation of its protective walls remains intact.
SAP has carved out a position that truly makes things difficult for the competition. Behind this lies the combined power of an assertive patent strategy, targeted partnerships, and solutions tailored specifically to individual sectors. The recent court settlement in the Celonis dispute also shows that the company continues to operate with confidence, even as regulatory authorities scrutinize its actions more closely. While Oracle and Microsoft are locked in a direct battle, SAP, with its closed ecosystem, has erected a barrier that is simply daunting for potential newcomers. The pivot toward becoming an AI-powered cloud provider is in full swing, and its patent protection ensures that it remains at the forefront of innovation. The share is currently trading at around EUR 135.80.
MustGrow Biologics: Driving the Agricultural Transition with Mustard-Based Technology and Bayer at Its Side
MustGrow Biologics has built a comprehensive patent portfolio around its mustard-based technology platform. At the core of the technology are the natural defensive compounds found in mustard plants. In particular, allyl isothiocyanate acts as a biological pesticide against soil-borne nematodes and fungal pathogens before completely breaking down without leaving harmful residues. The company has assembled an impressive international intellectual property portfolio, with approximately 110 granted or pending patents, covering everything from formulations and application methods to specific crop uses. This has resulted in a three-tier IP architecture that makes it extremely difficult for competitors to enter the market without obtaining a license. This protective barrier of process, formulation, and application patents goes far beyond conventional product protection, creating a substantial legal barrier to market entry.
The real catalyst, however, is MustGrow’s strategic partnership with Bayer. According to MustGrow’s estimates, the global agrochemical leader is expected to invest USD 35–40 million in the licensing and commercialization of the pre-registered mustard-derived biocontrol product TerraMG™ across Europe, the Middle East, and Africa (EMEA). After two years of field trials, Bayer was convinced of the product’s potential—a powerful endorsement from one of the industry’s leading players. The exclusive licensing agreement effectively makes the EMEA market inaccessible to competing products. While many biotech companies struggle for years to gain market access, Bayer is opening the doors to the world’s most important agricultural markets. At the same time, the US expansion of TerraSante™ is underway. The product has already been approved in ten states, including California, Texas, and Georgia—key regions for fruit and vegetable production.
MustGrow is pursuing a focused two-pillar strategy: TerraMG™ as a pre-registered biopesticide and TerraSante™ as a biofertility product. The company’s recent CAD 3.7 million capital increase is intended to expand production capacity. Two contract manufacturers in Asia currently have a near-term annual production capacity of approximately 500 tonnes of TerraSante™. Gross margins have already improved from 19.5% to 23.6%. With 63 million outstanding shares and a management stake of around 17%, the capital structure is sound. Over the next 12 to 18 months, US sales are expected to ramp up, potential approvals for TerraMG™ in Canada and the US could to be obtained, and the first milestone payments from Bayer are to be realized. The market for biological agricultural products is growing at an annual rate of 12–15%. MustGrow is therefore well positioned. The stock is currently trading at around CAD 0.39.
TSMC: Why the Chip Giant Is Staying the Course Despite Turbulence
The semiconductor market continues to be driven by the AI revolution. TSMC is benefiting particularly from this. The company recently reported a year-over-year revenue increase of around 35%, significantly exceeding analyst expectations. The main drivers are the highly specialized AI chips for major players like Nvidia and Microsoft, which are manufactured in Taiwan’s factories. The shift from simple AI tools to autonomous systems is creating additional demand here, and TSMC is delivering the necessary computing power with its cutting-edge sub-7-nanometer technologies.
What really sets TSMC apart are its three lines of defense—first, a massive patent portfolio. The company has been Taiwan’s patent king for a decade, securing manufacturing processes from transistor design to packaging—second, regulatory barriers. The US has pinned China to older technologies through its licensing policies. Taiwan, on the other hand, insists that the crown jewel of manufacturing, the 2-nm node, must be produced domestically. Added to this is a sophisticated yet predictable risk management strategy for legal disputes. The ongoing ITC proceeding regarding patent allegations is expected to be resolved in the summer of 2026 through an agreement between the parties.
TSMC combines a technological edge, regulatory backing, and locations in the US, Japan, and Germany under one roof. This positioning makes it incredibly difficult for competitors to replicate the company’s model. And even if the ITC proceedings were to result in a negative outcome in 2026, TSMC remains the only relevant supplier on the market for cutting-edge chips. Demand for AI continues to grow unabated, and TSMC holds the reins of the supply chain. The stock is currently trading at around USD 420.39.
The true competitive advantage of the 21st century is being inimitable. SAP secures its closed ecosystem against the competition with a robust patent portfolio and strategic partnerships. MustGrow Biologics leverages its unique mustard platform and powerful partner Bayer to potentially turn regulatory hurdles into billion-dollar markets. TSMC, finally, demonstrates that technological leadership paired with government backing is unbeatable. Those who bet on these three companies are investing in drivers of returns that will endure far beyond short-term market trends.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a “Transaction”). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
